1 citations
,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
The FDA did not approve a testosterone drug because of safety concerns.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
April 2023 in “Journal of Investigative Dermatology” The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
February 2023 in “Reactions Weekly” 2 citations
,
November 2025 in “British Journal of Pharmacology” Daprodustat, combined with PAβN, could be a new antibacterial treatment.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
10 citations
,
March 1990 in “The Journal of Dermatology” Long-term etretinate use may cause delayed wound healing and extra tissue growth after injury.
1 citations
,
June 2022 in “JAAD case reports” A woman developed a severe skin reaction after getting a birth control implant.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
June 2017 in “Journal of the American Academy of Dermatology” The new cream is safe and effective for mild to moderate atopic dermatitis.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
1 citations
,
April 2025 in “Skin Health and Disease” Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.
September 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Indometacin was chosen for a gel to help treat mastopathy and prevent breast cancer.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
Enemas can cause septicemia in elderly men with prostate infections.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
13 citations
,
April 2019 in “American Journal of PharmTech Research” Emulgels effectively deliver hydrophobic drugs for skin conditions like acne and psoriasis.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” The gene therapy showed significant wound healing and was safe for treating severe RDEB.